TABLE 1.
Characteristics of the normal and abnormal groups at the time of evaluation at the RVH
| Normal group | Abnormal group | P‐value (between normal and abnormal group) | 95% confidence interval | ||||
|---|---|---|---|---|---|---|---|
| Overall | HCM/HOCM | UCM | Other | ||||
| Age (y) | 7 (4‐11) | 9 (7‐11)* | 9 (7‐11) | 11 (10‐12)* | 9 (4‐11) | .04 | 0‐3 |
| Sex (M/F) (%) | 96/72 (57%/43%) | 30/19 (61%/39%) | 20/12 (63%/38%) | 3/6 (33%/67%) | 7/1 (87%/13%) | .63 | |
| Neutered (Y/N) (%) | 156/12 (93%/7%) | 44/5 (90%/10%) | 29/3 (91%/9%) | 9/0 (100%/0%) | 6/2 (75%/25%) | .55 | |
| BW (kg) | 5 (4‐6) | 5 (4‐6) | 5 (4‐6) | 6 (5‐7)* | 5 (4‐5) | .46 | 0‐1 |
| HR (bpm) | 198 (175‐220) | 186 (162‐216) | 195 (180‐228) | 195 (171‐212) | 150 (138‐117)* | .38 | −18‐6 |
| SBP (mm Hg) | 139 (131‐151) | 146 (136‐154) | 144 (137‐155) | 150 (142‐155) | 146 (128‐152) | .11 | −1‐10 |
| Creatinine (mg/dL) | 1.8 (1.6‐2.1) | 1.9 (1.5‐2.1) | 2 (1.6‐2.1) | 1.8 (1.6‐2.1) | 2 (1.5‐2.4) | .78 | −0.1‐0.2 |
| TT4 (μg/dL) | 2.4 (2.1‐2.8) | 2.4 (2.2‐2.8) | 2.4 (2.3‐2.8) | 2.5 (2.4‐2.7) | 2.4 (1.9‐3.2) | .6 | −0.1‐0.2 |
| IVSd‐M (mm) | 4.39 (3.82‐4.96) | 6.15 (4.38‐6.63)* | 6.49 (6.19‐6.94)* | 4.08 (3.36‐4.88) | 4.34 (3.47‐4.82) | <.001 | 0.96‐1.78 |
| LVFWd‐M (mm) | 4.27 (3.88‐4.93) | 5.1 (4.25‐6.57)* | 5.52 (5.003‐6.87)* | 4.59 (4.07‐4.78) | 4.18 (3.87‐5.22) | <.001 | 0.43‐1.16 |
| IVSd‐2D (mm) | 4.15 (3.53‐4.65) | 5.27 (4.5‐6.85)* | 6.2 (5.51‐6.94)* | 4.46 (4.1‐5.03) | 4.35 (4.08‐4.8) | .002 | 0.039‐0.209 |
| LVFWd‐2D (mm) | 4.24 (3.86‐4.79) | 5.45 (4.1‐6.06)* | 5.96 (5.23‐6.08)* | 4.87 (4.1‐5.47) | 4.25 (3.95‐5.15) | .02 | 0.021‐0.162 |
| IVS1‐2D (mm) | 4.53 (4.03‐4.99) | 6.24 (4.46‐6.75)* | 6.66 (6.17‐6.86)* | 4.31 (3.91‐5.09) | 4.75 (4.09‐4.97) | <.0001 | 0.103‐0.189 |
| IVS2‐2D (mm) | 4.14 (3.39‐4.77) | 5.12 (3.75‐5.81)* | 5.59 (5.03‐6.41)* | 4.48 (3.52‐5.22) | 4.64 (4.13‐5.02) | .02 | 0.17‐0.172 |
| Maximum LVWd (mm) | 4.84 (4.39‐5.27) | 6.39 (5.27‐7.07)* | 6.76 (6.42‐7.93)* | 4.95 (4.2‐5.55) | 5.02 (4.28‐5.23) | <.001 | 1.12‐1.82 |
| LA/Ao | 1.41 (1.27‐1.51) | 1.53 (1.31‐1.78)* | 1.5 (1.3‐1.72) | 1.82 (1.72‐1.84)* | 1.33 (1‐1.7) | .002 | 0.07‐0.25 |
Notes: Continuous variables are reported as median (interquartile range). Categorical variables are reported as number (%).
Abbreviations: bpm, beats per minute; BW, body weight; HCM, hypertrophic cardiomyopathy; HOCM, hypertrophic obstructive cardiomyopathy; HR, heart rate; IVS1‐2D, interventricular septal segment 1 thickness at end‐diastole on 2‐dimensional echocardiography; IVS2‐2D, interventricular septal segment 2 thickness at end‐diastole on 2‐dimensional echocardiography; IVSd‐2D, echocardiographic two‐dimensionally‐derived echocardiographic interventricular thickness in diastole; IVSd‐M, echocardiographic M‐mode‐derived interventricular thickness in diastole; LA : Ao, left‐atrial‐to‐aortic ratio; LVFWd‐2D, echocardiographic two‐dimensionally‐derived left ventricular free wall thickness; LVFWd‐M, echocardiographic M‐mode‐derived left ventricular free wall thickness; maximum LVWd, maximal diastolic left ventricular wall thickness measurement among IVSd‐M, LVFWd‐M, IVSd‐2D, LVFWd‐2D, IVS1‐2D, and IVS2‐2D; SBP, systemic arterial blood pressure; TT4, serum total thyroxine concentration; UCM, unclassified cardiomyopathy.
P < .05 (compared to normal group).